Key Takeaways
- President Trump has ordered the reclassification of cannabis from a Schedule I to a Schedule III drug, potentially easing financial pressure on marijuana businesses and expanding research opportunities.
- The change could improve access to banking, loans, and investment for the cannabis industry, as well as reduce tax burdens on businesses.
- The reclassification may also lead to increased research into the medical benefits of cannabis, potentially prompting corporations and larger businesses to enter the market.
- Michigan’s cannabis industry is expected to benefit from the change, with potential advantages including increased access to banking and loans, reduced tax burdens, and improved access to research funding.
Introduction to Cannabis Reclassification
The federal government has taken a significant step towards recognizing the medical value of marijuana, with President Trump ordering the reclassification of cannabis from a Schedule I to a Schedule III drug. This change, which will take effect in the second quarter of next year, has the potential to reshape medical research and ease financial pressure on marijuana businesses. Schedule I drugs are defined as having no accepted medical use and a high potential for abuse, while Schedule III drugs are treated as less risky and can be more easily researched with fewer regulatory controls.
Impact on Medical Research
The reclassification of cannabis is expected to lead to an increase in medical research into the benefits and risks of the drug. As Jerry Millen, owner of the Greenhouse Dispensary in Walled Lake, noted, "As soon as it goes into place, you’re going to start to see more studies. You’ll see attitudes start to change even more around cannabis." This increased research could lead to a greater understanding of the medical benefits of cannabis, potentially prompting corporations and larger businesses to enter the market and create new products.
Financial Benefits for Cannabis Businesses
The reclassification of cannabis is also expected to have significant financial benefits for marijuana businesses. Because cannabis was previously considered a Schedule I drug, business owners were unable to write off regular business costs like other companies, due to Internal Revenue Code Section 280E. However, with the change to Schedule III, business owners will likely be able to deduct operating expenses, salaries, and marketing costs, reducing their tax burden. As Ross Sloan, cannabis banking officer at Dart Bank, noted, "One of the most positive impacts" of rescheduling marijuana at the federal level will likely be opening up existing tax breaks and deductions that businesses had not previously qualified for.
Access to Banking and Loans
The reclassification of cannabis may also improve access to banking and loans for marijuana businesses. Currently, banks are reluctant to work with the industry due to the federal illegality of marijuana, making it difficult for business owners to open bank accounts or apply for business loans. However, with the change to Schedule III, banks may be more willing to work with the industry, reducing the risks associated with cash-based transactions and increasing access to capital.
Challenges for Michigan’s Cannabis Industry
Despite the potential benefits of the reclassification, Michigan’s cannabis industry is still facing significant challenges. Sales have been slowing and prices have been dropping amidst oversupply and increased competition in recent years. The industry is also set to face a new 24% wholesale tax, which was adopted by Gov. Gretchen Whitmer and state legislators to help raise money for long-term road repairs. However, the reclassification of cannabis may trigger more interest in the drug’s medical benefits, potentially prompting corporations and larger businesses to enter the market and create new products.
Future of Cannabis Regulation
The reclassification of cannabis is a significant step towards recognizing the medical value of marijuana, but it is only the beginning. As Brian Hanna, Executive Director of Michigan’s Cannabis Regulatory Agency, noted, "This development has the potential to move the federal marijuana policy debate forward after years of advocacy by patients, businesses, and states across the country." However, without clear guidance and thoughtful implementation, the challenges faced by patients, businesses, financial institutions, and state regulators will not be unilaterally resolved. The federal government must provide clear guidance on the implications of the reclassification, including its impact on banking, taxation, and research, in order to fully realize the benefits of this change.